The Fermiscan Test is a safe, non-invasive technology that utilises X-ray diffraction of hair fibres to screen and monitor women of all ages for breast cancer. The Fermiscan Test will be available for women in Australia in 2008 and Fermiscan is also commencing further clinical trials and regulatory approval processes in the US.
The Fermiscan Test requires individuals to supply 20 strands of untreated scalp hair with a minimum length of 30 mm. The hairs are then exposed to a finely focused X-ray beam for up to 30 s. The diffracted X-rays are collected as an image which is then analysed to determine if subtle changes are present in the image that are indicative of the presence of breast cancer.
Phone: 02 9245 4460
Lonza TheraPEAK AmpliCell Cytokines and TheraPEAK 293-GT Medium
The products provide researchers and manufacturers with high-performance, scalable and...
Grace Bio-Labs protein microarray tools
Grace Bio-Labs' microarray substrates provide high binding capacity and enable high assay...
Siemens Healthineers 3gAllergy assay
Siemens Healthineers has expanded its 3gAllergy assay menu with nine additional component...
